Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2018 Apr 26

PMID 29690599

Citations 76

Authors

Kentaro Inamura

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide, with lung adenocarcinoma representing the most common lung cancer subtype. Among all lung adenocarcinomas, the most prevalent subset develops via tumorigenesis and progression from atypical adenomatous hyperplasia (AAH) to adenocarcinoma in situ (AIS), to minimally invasive adenocarcinoma (MIA), to overt invasive adenocarcinoma with a lepidic pattern. This stepwise development is supported by the clinicopathological and molecular characteristics of these tumors. In the 2015 World Health Organization classification, AAH and AIS are both defined as preinvasive lesions, whereas MIA is identified as an early invasive adenocarcinoma that is not expected to recur if removed completely. Recent studies have examined the molecular features of lung adenocarcinoma tumorigenesis and progression. -mutated adenocarcinoma frequently develops via the multistep progression. Oncogene-induced senescence appears to decrease the frequency of the multistep progression in - or -mutated adenocarcinoma, whose tumor evolution may be associated with epigenetic alterations and kinase-inactive mutations. This review summarizes the current knowledge of tumorigenesis and tumor progression in early lung adenocarcinoma, with special focus on its clinicopathological characteristics and their associations with driver mutations (, , and ) as well as on its molecular pathogenesis and progression.

Citing Articles

RFX2 downregulates RASSF1 expression and YAP phosphorylation through Hippo signaling to promote immune escape in lung adenocarcinoma.

Kong Z, Zhou P, Xu J, Zhang Y, Wang Y Cell Div. 2025; 20(1):7.

PMID: 40069841 PMC: 11895337. DOI: 10.1186/s13008-025-00147-z.

Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis.

Bi L, Wang X, Li J, Li W, Wang Z MedComm (2020). 2025; 6(3):e70080.

PMID: 39991629 PMC: 11843169. DOI: 10.1002/mco2.70080.

Halo Sign and Reverse Halo Sign in a Patient with Primary Lung Adenocarcinoma: A Case Report.

Ebrahimi P, Jamaati H, Soleimani A Tanaffos. 2025; 23(2):209-212.

PMID: 39959800 PMC: 11825078.

The mathematical exploration for the mechanism of lung adenocarcinoma formation and progression.

Han Y, Chen B, Bi Z, Bian J, Kang R, Shang X Brief Bioinform. 2024; 25(6).

PMID: 39562161 PMC: 11576079. DOI: 10.1093/bib/bbae603.

Integrated analysis of single-cell and bulk RNA-sequencing identifies a metastasis-related gene signature for predicting prognosis in lung adenocarcinoma.

Cao X, Xi J, Wang C, Yu W, Wang Y, Zhu J Clin Transl Oncol. 2024; .

PMID: 39516442 DOI: 10.1007/s12094-024-03752-6.

References

Murakami S, Ito H, Tsubokawa N, Mimae T, Sasada S, Yoshiya T . Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma. Lung Cancer. 2015; 90(2):199-204. DOI: 10.1016/j.lungcan.2015.06.022. View

Cappuzzo F, Hirsch F, Rossi E, Bartolini S, Ceresoli G, Bemis L . Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005; 97(9):643-55. DOI: 10.1093/jnci/dji112. View

Kim H, Shim Y, Lee K, Han J, Yi C, Kim Y . Persistent pulmonary nodular ground-glass opacity at thin-section CT: histopathologic comparisons. Radiology. 2007; 245(1):267-75. DOI: 10.1148/radiol.2451061682. View

Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M . Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy. Chest. 2014; 145(1):66-71. DOI: 10.1378/chest.13-1094. View

Liu S, Wang R, Zhang Y, Li Y, Cheng C, Pan Y . Precise Diagnosis of Intraoperative Frozen Section Is an Effective Method to Guide Resection Strategy for Peripheral Small-Sized Lung Adenocarcinoma. J Clin Oncol. 2015; 34(4):307-13. DOI: 10.1200/jco.2015.63.4907. View

He P, Yao G, Guan Y, Lin Y, He J . Diagnosis of lung adenocarcinoma in situ and minimally invasive adenocarcinoma from intraoperative frozen sections: an analysis of 136 cases. J Clin Pathol. 2016; 69(12):1076-1080. DOI: 10.1136/jclinpath-2016-203619. View

Maeshima A, Tochigi N, Yoshida A, Asamura H, Tsuta K, Tsuda H . Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: a reliable prognostic indicator. J Thorac Oncol. 2010; 5(3):333-9. DOI: 10.1097/JTO.0b013e3181c8cb95. View

Sholl L, Yeap B, Iafrate A, Holmes-Tisch A, Chou Y, Wu M . Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res. 2009; 69(21):8341-8. PMC: 2783286. DOI: 10.1158/0008-5472.CAN-09-2477. View

Yeh Y, Nitadori J, Kadota K, Yoshizawa A, Rekhtman N, Moreira A . Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ≤ 3 cm: accuracy and interobserver agreement. Histopathology. 2014; 66(7):922-38. PMC: 4536823. DOI: 10.1111/his.12468. View

10.

Dimri G, Lee X, Basile G, Acosta M, Scott G, Roskelley C . A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995; 92(20):9363-7. PMC: 40985. DOI: 10.1073/pnas.92.20.9363. View

11.

Narita M, Nunez S, Heard E, Narita M, Lin A, Hearn S . Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003; 113(6):703-16. DOI: 10.1016/s0092-8674(03)00401-x. View

12.

Nakanishi H, Matsumoto S, Iwakawa R, Kohno T, Suzuki K, Tsuta K . Whole genome comparison of allelic imbalance between noninvasive and invasive small-sized lung adenocarcinomas. Cancer Res. 2009; 69(4):1615-23. DOI: 10.1158/0008-5472.CAN-08-3218. View

13.

Nieto P, Ambrogio C, Esteban-Burgos L, Gomez-Lopez G, Blasco M, Yao Z . A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature. 2017; 548(7666):239-243. PMC: 5648056. DOI: 10.1038/nature23297. View

14.

Borczuk A, Qian F, Kazeros A, Eleazar J, Assaad A, Sonett J . Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol. 2008; 33(3):462-9. PMC: 2987634. DOI: 10.1097/PAS.0b013e318190157c. View

15.

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

16.

Inamura K . Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. Front Oncol. 2017; 7:193. PMC: 5581350. DOI: 10.3389/fonc.2017.00193. View

17.

Travis W, Brambilla E, Burke A, Marx A, Nicholson A . Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol. 2015; 10(9):1240-1242. DOI: 10.1097/JTO.0000000000000663. View

18.

Koga T, Hashimoto S, Sugio K, Yoshino I, Mojtahedzadeh S, Matsuo Y . Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma. Clin Cancer Res. 2001; 7(6):1730-8. View

19.

Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K . The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006; 9(6):485-95. DOI: 10.1016/j.ccr.2006.04.022. View

20.

Robinson W, Lemon M, Elefanty A, Markham N, Norris D . Human acquired naevi are clonal. Melanoma Res. 1999; 8(6):499-503. DOI: 10.1097/00008390-199812000-00004. View